Boston Scientific Corporation

Boston Scientific Corporation

BSX·NYSE

$47.69

-0.60%
HealthcareMedical - Devices

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

At a Glance

Live Snapshot
Market Cap$70.88B
EPS1.9600
P/E Ratio24.33
Earnings Date07/22/2026

bsx

Operating Cash Flow

Last Annual Value

4.53B

3-Year CAGR

44%

5-Year CAGR

25%

10-Year CAGR

22%

Boston Scientific Corporation

Boston Scientific Corporation Competitors Analysis of Operating Cash Flow

BSX · NYSE
CompanyOperating Cash Flow
CAGR 3Y
CAGR 5Y
CAGR 10Y
4.53B
21.9%19.4%16.6% 
7.04B
5.3%2.5%3.0%
PFE logo
Pfizer Inc.
NYSE:PFE
11.71B
10.4%-18.5%-3.0%
9.57B
9.6%-1.9%11.6%
12.64B
10.2%7.1%8.4%
10.02B
7.8%-2.5%-5.2%
6.16B
6.1%6.3%5.3%
6.42B
-3.6%-5.2%6.2%
AMGN logo
Amgen Inc.
NASDAQ:AMGN
9.96B
5.5%1.5%-0.4%
5.04B
10.8%9.1%10.2%
Boston Scientific Corporation

Boston Scientific Corporation Fair Value Envelope

BSX · NYSE

Our analysis suggests that BSX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.69, this represents a potential HIDDEN relative to our calculated worth for Boston Scientific Corporation.

Intrinsic Value
Current Price: $47.69